Two Medical Device Dividend Giants, One Better Buy: Medtronic vs. Abbott

Medtronic is favored for retirement-focused income investors, offering a 3.11% dividend yield versus Abbott's 2.4%, a lower 15x forward P/E versus 17x, and raised FY27 organic revenue growth guidance of 7.25%-7.75%. Medtronic's Q1 FY27 revenue grew 13.7% year over year to $9.76 billion, while Abbott's Q2 2026 revenue rose 13.0% to $12.59 billion, supported by medical devices and its $21 billion Exact Sciences acquisition. Abbott remains the preferred long-horizon quality and compounding choice, having delivered a 202.76% 10-year return versus Medtronic's 39.83%, but Medtronic's execution against FY27 EPS guidance of $5.94-$6.00 is the key risk to the bullish income case.

Analysis

MDT’s apparent discount is less a dividend-value signal than a separation/execution discount. A clean Diabetes spin can improve the remaining company’s growth and capital-allocation narrative, but only if stranded costs, transition-service expenses, and dis-synergies do not consume the expected multiple uplift; the first post-separation guidance framework is the key 3-9 month catalyst. The market is likely to reward sustained procedure-led growth with a 1-2x forward-P/E rerating, but a guide-down would quickly expose the stock as a mature-device business whose yield is compensating for lower confidence.

ABT’s quality premium now embeds a materially more complicated earnings bridge. Exact Sciences adds oncology-screening optionality and diagnostic-channel scale, but acquisition accounting, financing costs, integration execution, and reimbursement adoption can depress reported EPS and margins before revenue synergies become visible. This creates a likely 1-3 quarter period in which ABT can screen optically expensive despite intact long-term franchise quality; EXAS shareholders have already captured much of the straightforward deal premium, while ABT holders now own the integration risk.

The clean tactical expression is long MDT versus short ABT, rather than an outright broad medtech long: both retain hospital-capex and reimbursement exposure, while the spread isolates MDT’s operational acceleration and separation catalyst against ABT’s acquisition digestion. Contrarian risk is that MDT’s recent growth is concentrated in faster-growing procedure categories that can normalize sharply as comparisons harden, whereas ABT’s diversified installed base may prove more defensive if hospital budgets weaken. Falsification: MDT cutting its FY27 EPS range or organic-growth outlook, or ABT demonstrating acquisition-related margin resilience and accelerating oncology-screening revenue by the next two earnings reports.

Key Decisions for Investors

• Initiate a 3-6 month long MDT / short ABT dollar-neutral pair on weakness, targeting 8-12% relative upside; exit if MDT reduces FY27 EPS guidance or if ABT raises its post-acquisition margin outlook.
• For directional healthcare exposure, accumulate MDT only below approximately 16x forward EPS or after confirmation that the Diabetes separation does not require a material standalone-cost reset; target a 1-2x multiple rerating over 6-12 months, with downside defined by a guidance miss.
• Do not chase EXAS after the strategic transaction: monitor for any residual spread to confirmed consideration, but absent a revised bid or regulatory complication, the remaining risk/reward is dominated by closing and deal-arbitrage mechanics rather than operating upside.
• Use ABT as a watch-list long for a 6-18 month horizon rather than immediate purchase: reassess after two quarters of disclosed Exact integration metrics, especially diagnostic growth, deal-related dilution, and free-cash-flow conversion. A persistent margin shortfall would justify further multiple compression.